Home
OE Originals
OE Insights
CME
All Specialties
Arthroplasty
Cannabis
Ev. Based Medicine
Foot & Ankle
General Orthopaedics
Hand & Wrist
Metabolic Disorders
Osteoarthritis
Pediatric Orthopaedics
Peri-Operative
Phys. Therapy & Rehab
Shoulder & Elbow
Spine
Sports Medicine
Trauma
Tumour

Author Interviews

Conference Reports

PeerView

All Videos
(188 Videos)

Leadership
(1 Videos)
Research
(1 Videos)
OrthoJoe
(57 Videos)
Webinar
(9 Videos)
OE Headline
(7 Videos)
OrthoPod
(113 Videos)

COVID-19 Resource Center

OE World Tour

OE Perspectives

OE Ideas

OE Recommends

To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Previous OE Original
Use of Transcutaneous Electrical Nerve Stimulation (TENS) for Management of Pain Following Total Knee Arthroplasty: A Systematic Review
Next OE Original
Trends in Physical Therapy & Rehabilitation: A Detailed Data Report Powered by OE M.I.N.D.
OE Original Cover

Tanezumab Versus NSAIDs in the Treatment of Hip or Knee Osteoarthritis: A Systematic Review and Meta-analysis of Randomized Clinical Trials

Share
Cite This
+ Favorites
Share
Cite This
+ Favorites
July 11, 2022

Tanezumab Versus NSAIDs in the Treatment of Hip or Knee Osteoarthritis: A Systematic Review and Meta-analysis of Randomized Clinical Trials

Vol: 5| Issue: 7| Number:2| ISSN#: 2563-559X

Authored By: Meng Zhu, Yaping Chang, Steve Phillips, Ellen Scholl, Selina Bains, Mohit Bhandari on behalf of OrthoEvidence

Banner Image
Highlights
  • In the present OE Original, we conduct a systematic review and meta-analysis to examine evidence from randomized controlled trials (RCTs) comparing the efficacy and safety of tanezumab (2.5 mg or 5 mg) administered intravenously or subcutaneously with oral non-steroidal anti-inflammatory drugs (NSAIDs) in patients with hip or knee osteoarthritis (OA).

 

  • Six studies, representing 4 RCT cohorts, were identified. All studies were sponsored by Pfizer.

 

  • Tanezumab 2.5 mg significantly improved WOMAC pain, WOMAC function, and PGA only at 4 weeks post treatment, but not at 16 weeks after treatment. In addition, tanezumab 2.5 mg resulted in an elevated risk of developing rapidly progressive OA, compared to NSAIDs.

 

  • Tanezumab 5 mg, more efficacious than 2.5 mg tanezumab, markedly improved all efficacy outcomes at both 4 weeks and 16 weeks post treatment. However, such benefits might not be clinically important. More importantly, tanezumab 5 mg raised more safety concerns: it significantly increased the risk of developing any adverse event, rapidly progressive OA, and abnormal peripheral sensation, compared to oral NSAIDs.

 

  • There lacks convincing evidence demonstrating that the benefits of tanezumab 2.5 mg or 5 mg outweigh the harms.

To view the full content, login to your account,
or start your 30-day FREE Trial today.

FREE TRIAL Forgot Password?

Explore some of our unlocked OE Originals below!

 Evaluation of Clinical and Safety Outcomes of Robotic Arm-assisted Versus Conventional Unicompartmental Knee Arthroplasty: A Systematic Review of Randomized Controlled Trials
Platelet-rich Plasma (PRP) Injection Versus Control for Rotator Cuff Tendinopathy: Powered by OE M.I.N.D.
Surgical Versus Non-surgical Treatment for ACL Injury: Powered by OE M.I.N.D.
Colchicine for Knee Osteoarthritis: A Systematic Review and Meta-analysis
OE OriginalPreview Image

SHARE THIS OE ORIGINAL

Loading...

Recommended OE Originals

Users who read this report also read the following OE Originals:

Join the Conversation

Please Login or Join to leave comments.

Frank Smith 2022-07-14

Orthopaedic Surgeon - Canada

Very disappointing longer term findings after a promising start.So many studies copy this direction: steroid injections, partiai meniscectomies etc. The role of more modern regenerative medicine needs deeper study than any done so far by OE.